Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garcés T, Pacheco MI, Flohr P, Massard C, López-Casas PP, Castro E, de Bono JS, Olmos D. Lozano R, et al. Among authors: rescigno p. Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334. Cancers (Basel). 2021. PMID: 34066080 Free PMC article.
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. Ferraldeschi R, et al. Among authors: rescigno p. Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4. Eur Urol. 2015. PMID: 25454616 Free PMC article.
Plasma AR and abiraterone-resistant prostate cancer.
Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G. Romanel A, et al. Among authors: rescigno p. Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511. Sci Transl Med. 2015. PMID: 26537258 Free PMC article.
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS. Rescigno P, et al. Eur Urol. 2016 Nov;70(5):724-731. doi: 10.1016/j.eururo.2016.02.055. Epub 2016 Mar 7. Eur Urol. 2016. PMID: 26965561 Free article.
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR. Welti J, et al. Among authors: rescigno p. Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23. Eur Urol. 2016. PMID: 27117751 Free PMC article.
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Rescigno P, de Bono JS. Rescigno P, et al. Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27. Eur Urol. 2016. PMID: 27240941 No abstract available.
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Perez-Lopez R, et al. Among authors: rescigno p. Radiology. 2017 Apr;283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22. Radiology. 2017. PMID: 27875103 Free PMC article. Clinical Trial.
134 results